Department of Radiology, Severance Hospital, Yonsei University College of Medicine, Seoul, Republic of Korea.
Korean J Radiol. 2024 Mar;25(3):257-266. doi: 10.3348/kjr.2023.0712.
To investigate molecular and functional consequences of additional exposures to iodine- or gadolinium-based contrast agents within 24 hours from the initial intravenous administration of iodine-based contrast agents through an animal study.
Fifty-six Sprague-Dawley male rats were equally divided into eight groups: negative control, positive control (PC) with single-dose administration of CT contrast agent, and additional administration of either CT or MR contrast agents 2, 4, or 24 hours from initial CT contrast agent injection. A 12 µL/g of iodinated contrast agent or a 0.47 µL/g of gadolinium-based contrast agent were injected into the tail vein. Serum levels of blood urea nitrogen, creatinine, cystatin C (Cys C), and malondialdehyde (MDA) were measured. mRNA and protein levels of kidney injury molecule-1 (KIM-1) and neutrophil gelatinase-associated lipocalin (NGAL) were evaluated.
Levels of serum creatinine (SCr) were significantly higher in repeated CT contrast agent injection groups than in PC (0.21 ± 0.02 mg/dL for PC; 0.40 ± 0.02, 0.34 ± 0.03, and 0.41 ± 0.10 mg/dL for 2-, 4-, and 24-hour interval groups, respectively; < 0.001). There was no significant difference in the average Cys C and MDA levels between PC and repeated CT contrast agent injection groups (Cys C, = 0.256-0.362; MDA, > 0.99). Additional doses of MR contrast agent did not make significant changes compared to PC in SCr ( > 0.99), Cys C ( = 0.262), and MDA ( = 0.139-0.771) levels. mRNA and protein levels of KIM-1 and NGAL were not significantly different among additional CT or MR contrast agent groups ( > 0.05).
A sufficient time interval, probably more than 24 hours, between repeated contrast-enhanced CT examinations may be necessary to avoid deterioration in renal function. However, conducting contrast-enhanced MRI on the same day as contrast-enhanced CT may not induce clinically significant kidney injury.
通过动物研究,探讨在首次静脉注射碘造影剂后 24 小时内再次接触碘或钆基造影剂对机体的分子和功能影响。
56 只雄性 Sprague-Dawley 大鼠等分为 8 组:阴性对照组、单次 CT 造影剂组(PC)、CT 造影剂后 2、4、24 小时再次给予 CT 或 MR 造影剂。尾静脉注射 12μL/g 的碘造影剂或 0.47μL/g 的钆基造影剂。检测血尿素氮、肌酐、胱抑素 C(Cys C)和丙二醛(MDA)水平,评估肾损伤分子-1(KIM-1)和中性粒细胞明胶酶相关脂质运载蛋白(NGAL)的 mRNA 和蛋白水平。
与 PC 组相比,重复 CT 造影剂注射组的血清肌酐(SCr)水平显著升高(PC 组:0.21 ± 0.02mg/dL;2 小时间隔组:0.40 ± 0.02mg/dL;4 小时间隔组:0.34 ± 0.03mg/dL;24 小时间隔组:0.41 ± 0.10mg/dL; <0.001)。PC 组与重复 CT 造影剂注射组的平均 Cys C 和 MDA 水平无显著差异(Cys C: = 0.256-0.362;MDA: >0.99)。与 PC 组相比,MR 造影剂的额外剂量对 SCr( >0.99)、Cys C( = 0.262)和 MDA( = 0.139-0.771)水平无显著影响。在 CT 或 MR 造影剂的额外剂量组中,KIM-1 和 NGAL 的 mRNA 和蛋白水平无显著差异( >0.05)。
在重复增强 CT 检查之间,可能需要至少 24 小时的充分时间间隔,以避免肾功能恶化。然而,在同一天进行增强 CT 和增强 MRI 检查可能不会导致临床上显著的肾损伤。